Keros Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
KROS$9.17-2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2025 | 2024 | |
| REVENUE: | ||
| Service and other revenue | $38,706 | $550 |
| License revenue | 205,355 | 3,000 |
| Total revenue | 244,061 | 3,550 |
| OPERATING EXPENSES: | ||
| Research and development | (129,643) | (173,629) |
| General and administrative | (46,849) | (40,754) |
| Total operating expenses | (176,492) | (214,383) |
| INCOME (LOSS) FROM OPERATIONS | 67,569 | (210,833) |
| OTHER INCOME (EXPENSE), NET: | ||
| Research and development incentive income | — | 1,238 |
| Dividend income | 24,867 | 23,496 |
| Other expense, net | (539) | (954) |
| Total other income, net | 24,328 | 23,780 |
| Income (loss) before income taxes | 91,897 | (187,053) |
| Income tax provision | (4,883) | (300) |
| Net income (loss) | $87,014 | $(187,353) |
| Net income (loss) attributable to common stockholders — basic and diluted (Note 11) | $87,014 | $(187,353) |
| Weighted-average common stock outstanding—basic | 37,221,211 | 37,437,652 |
| Weighted-average common stock outstanding—diluted | 37,859,106 | 37,437,652 |
| Net income (loss) per share of common stock — basic | $2.34 | $(5.00) |
| Net income (loss) per share of common stock — diluted | $2.30 | $(5.00) |
Consolidated Statements of Stockholders’ Equity
| COMMON STOCK$0.0001 PAR VALUE · TREASURY STOCK · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · TOTAL STOCKHOLDERS’ EQUITY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHARES · AMOUNT · SHARES · AMOUNT | |||||||||||
| BALANCE, January 1, 2024 | 31,841,084 | $3 | — | $— | $713,636 | $(381,426) | $332,213 | ||||
| Issuance of common stock, net of underwriting discounts, commissions and offering costs of $9,943 | 4,025,000 | — | — | — | 151,057 | — | 151,057 | ||||
| Issuance of common stock under the ATM agreement, net of commissions and offering cost of $3,655 | 4,290,096 | 1 | — | — | 228,622 | — | 228,623 | ||||
| Exercise of common stock options | 398,525 | — | — | — | 12,141 | — | 12,141 | ||||
| Stock-based compensation | — | — | — | — | 34,872 | — | 34,872 | ||||
| Net income (loss) | — | — | — | — | — | (187,353) | (187,353) | ||||
| BALANCE, December 31, 2024 | 40,554,705 | $4 | — | $— | $1,140,328 | $(568,779) | $571,553 | ||||
| Issuance of common stock under the employee stock purchase plan | 11,806 | — | — | — | 138 | — | 138 | ||||
| Repurchase of treasury stock, including excise tax, direct fees and expenses of $9,558 | — | — | (21,126,760) | (384,558) | — | — | (384,558) | ||||
| Short-swing profit settlement | — | — | — | — | 139 | — | 139 | ||||
| Exercise of common stock options | 73,655 | — | — | — | 150 | — | 150 | ||||
| Vesting of restricted stock units | 30,300 | — | — | — | — | — | — | ||||
| Stock-based compensation | — | — | — | — | 28,696 | — | 28,696 | ||||
| Net income (loss) | — | — | — | — | — | 87,014 | 87,014 | ||||
| BALANCE, December 31, 2025 | 40,670,466 | $4 | (21,126,760) | $(384,558) | $1,169,451 | $(481,765) | $303,132 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.